Table 2.

Donor characteristics

PID	Gender	Maximum pre-ART viral load,* c/mL	CD4+ nadir, cells/µL	Approximate years of infection before initial ART	Current ART regimen	Total years of ART experience	Years of viral suppression on ART at sampling	Plasma viral load on ART, c/mL	CD4+ on ART, cells/µL
Patient 1†	Male	412,033	16	Unknown	TDF, FTC, RTG	13	1.0, not suppressed	<50, 134	137, 153
1683	Male	134,406	452	2.0	FTC, TDF, RTV, DRV	5.7	5.4	<40	1,348
2669‡	Male	Unknown	205	≤22.0	ABC, 3TC, DTG	5.5	4.3	<40	681
3162‡	Male	171,000	147	11.0	RTV, DRV, ABC, DTG, 3TC‡	20	11.2	<40	558
R-09	Male	97,000	105	Unknown	EFV, FTC, TDF	9.8	5.3§	≤133	380

^*Abbott Diagnostics RealTime HIV-1 PCR Assay.

^†Same donor as in refs. 1 and 10; 2 time points, 6 mo apart.

^‡ART failure due to drug resistance (Fig. 4) prior to suppression on new regimen including dolutegravir.

^§PID R-09 maintained viral suppression ≤133 copies/mL for 5.3 y and <40 copies/mL for 0.9 y prior to sample time point.